1. ALLA AKTIER
  2. NYHETER
  3. LIPUM

Lipum

Nyheter Lipum Nyheter alla bolag

Lipum to participate in following upcoming events

Lipum (publ), a clinical stage biopharmaceutical company focused on chronic inflammatory diseases, today announced its participation in the following upcoming events.

BIO-Europe Spring | March 20–22, 2023 | Basel, Switzerland
LSX World Congress | May 3-4, 2023 | London, UK
Redeye Investor Forum | May 11, 2023 | Malmö, Sweden
BioStock Life Science Summit Spring | May 30-31, 2023 | Digital
BIO International Convention | June 5-8, 2023 | Boston, MA, USA
 
“Our phase 1 clinical study on the lead candidate SOL-116 is ongoing and industry meetings provide opportunities to maintain our contacts and present the progress”, says CEO Einar Pontén.

Contacts
Einar Pontén, CEO
E-post: einar.ponten@lipum.se
Mobile: +46 70 578 34 95
Web: www.lipum.se

About Us
Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

Attachments
Lipum to participate in following upcoming events

Datum 2023-02-07, kl 13:00
Källa MFN
Bifogade filer
Lipum to participate in following upcoming events
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!